Kalshi is offering NY Post readers a $10 bonus when they open an account and enter the promo code NYPMAX. Upon sign-up, all ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo ...

--Down 48.34% year-to-date; on pace for worst year since 1984, when it fell 57.59% --Down 69.75% from its all-time closing high of $146.91 on June 25, 2024 --Down 57.50% from 52 weeks ago (Nov. 25, ...

Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Pfizer has won the ...

Novo Nordisk, Eli Lilly agree to lower GLP-1 drug prices in US Analysts see short-term revenue hit, long-term volume boost FDA weighs expedited Novo obesity pill review, Lilly yet to submit The deal ...

Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 ...

As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech declaring Novo's offer "superior"—even though it has already inked an ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform. The discussions are about both ...

Novo Nordisk A/S found a new leader for its investor relations department in an equity analyst who has recommended buying shares in the drugmaker for almost 15 years. Michael Novod, one the best known ...

Novo Nordisk NOVO B announced plans on Oct. 9 to acquire Akero Therapeutics and its phase 3 FGF21 analog efruxifermin for USD 4.7 billion upfront and a potential additional USD 500 million contingent ...